Sprint Bioscience AB (publ) (STO: SPRINT)
1.240
0.00 (0.00%)
Sep 11, 2024, 5:00 PM CET
Sprint Bioscience AB Revenue
Sprint Bioscience AB had revenue of 16.70M SEK in the quarter ending June 30, 2024, with 40,629.27% growth. This brings the company's revenue in the last twelve months to 86.21M, up 141,234.43% year-over-year. In the year 2023, Sprint Bioscience AB had annual revenue of 51.69M with 62,171.08% growth.
Revenue (ttm)
86.21M
Revenue Growth
+141,234.43%
P/S Ratio
1.00
Revenue / Employee
2.39M
Employees
28
Market Cap
86.58M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 51.69M | 51.60M | 62,171.08% |
Dec 31, 2022 | 83.00K | -34.95M | -99.76% |
Dec 31, 2021 | 35.03M | 15.83M | 82.49% |
Dec 31, 2020 | 19.20M | -14.62M | -43.23% |
Dec 31, 2019 | 33.81M | 15.88M | 88.51% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca PLC | 520.76B |
Swedish Orphan Biovitrum AB (publ) | 23.71B |
Getinge AB (publ) | 33.33B |
Camurus AB (publ) | 1.59B |
Vitrolife AB (publ) | 3.54B |
Medicover AB (publ) | 21.70B |
Elekta AB (publ) | 18.12B |
Vimian Group AB (publ) | 3.91B |